Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Colulintide (LY3541105) in Healthy and Overweight Participants
NCT05380323Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of colulintide in obesity and Overweight (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment Emergent Adverse Events at 26 weeks. Started May 2022; status: completed.
02
Drugs
colulintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05380323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380323.